19062-Lymphomas-NA-150

Lymphomas

A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

  • Details

ClinicalTrials.gov ID: NCT04224493
Diagnosis Type: NA
USOR Number:

  • Address

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

Search by practice name, trial titles, indicators and specific disease types.